BE666424A - - Google Patents

Info

Publication number
BE666424A
BE666424A BE666424DA BE666424A BE 666424 A BE666424 A BE 666424A BE 666424D A BE666424D A BE 666424DA BE 666424 A BE666424 A BE 666424A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE666424A publication Critical patent/BE666424A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE666424D 1965-05-12 1965-07-05 BE666424A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2813865 1965-05-12
JP2834265 1965-05-13

Publications (1)

Publication Number Publication Date
BE666424A true BE666424A (enExample) 1966-01-05

Family

ID=26366189

Family Applications (1)

Application Number Title Priority Date Filing Date
BE666424D BE666424A (enExample) 1965-05-12 1965-07-05

Country Status (4)

Country Link
BE (1) BE666424A (enExample)
CH (1) CH464935A (enExample)
DE (1) DE1620284C3 (enExample)
FR (1) FR4491M (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6258918B2 (ja) * 2012-04-10 2018-01-10 アンジー ファーマスーティカル カンパニー リミテッドAnnji Pharamaceutical Co., Ltd. ヒストンデアセチラーゼ(hdacs)阻害剤

Also Published As

Publication number Publication date
DE1620284C3 (de) 1974-10-24
DE1620284B2 (de) 1974-03-21
CH464935A (de) 1968-11-15
FR4491M (enExample) 1966-10-10
DE1620284A1 (de) 1970-03-12

Similar Documents

Publication Publication Date Title
BE676223A (enExample)
JPS4411847Y1 (enExample)
JPS4325003Y1 (enExample)
JPS425844Y1 (enExample)
JPS4411655Y1 (enExample)
JPS4221765Y1 (enExample)
JPS4431467Y1 (enExample)
JPS4312397Y1 (enExample)
JPS5113729B1 (enExample)
BE675122A (enExample)
BE676062A (enExample)
BE674937A (enExample)
BE661161A (enExample)
BE669379A (enExample)
BE674635A (enExample)
SE310891B (enExample)
BE674580A (enExample)
BE675028A (enExample)
NL6609553A (enExample)
BE675035A (enExample)
BE673712A (enExample)
BE675379A (enExample)
BE660391A (enExample)
BE676093A (enExample)
BE675101A (enExample)